Quick Answer
Greenwich LifeSciences, Inc. reported Total Assets of $4.09 million for the year ending 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -41.5% in Total Assets from 2023 to 2024.
- This data is from Greenwich LifeSciences, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $6.27 million | Q1 2021: $30.42 million | Q2 2021: $29.82 million | Q3 2021: $28.92 million | Q1 2022: $19.75 million | Q2 2022: $17.20 million | Q3 2022: $15.65 million | Q1 2023: $11.92 million | Q2 2023: $10.95 million | Q3 2023: $9.15 million | Q1 2024: $5.51 million | Q2 2024: $7.23 million | Q3 2024: $5.83 million | Q4 2024: $4.09 million | Q1 2025: $2.75 million | Q2 2025: $3.13 million | Q3 2025: $3.81 million.
- Over the full 6 years of available data (2019 to 2024), Greenwich LifeSciences, Inc.'s Total Assets has grown by 15,249.1%.
- Historical annual values: Fiscal year 2024: $4.09 million | Fiscal year 2023: $6.99 million | Fiscal year 2022: $13.48 million | Fiscal year 2021: $27.22 million | Fiscal year 2020: $28.68 million | Fiscal year 2019: $26.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: